Abstract: Objective To explore the association of the gene amplification of c-Met with the clinical and pathological features in non-small cell lung cancer（NSCLC） patients， and the correlation with other driver genes such as EGFR， K-Ras and EML4-ALK. Methods The c-Met gene amplification status was detected by fluorescence in situ hybridization（FISH） in the 108 cases of NSCLC specimens. The expression of c-Met and EML4-ALK fusion gene were detected by real-time quantitative PCR（qRT-PCR）. Mutations of EGFR and KRas were detected using PCRbased direct sequencing. The correlation of the gene amplification of c-Met with clinicopathologic features and the other driver genes such as EGFR， K-Ras， and EML4-ALK was analyzed. Results （1） Among 108 NSCLC patients， c-Met gene amplification was observed in two cases（1.85％）. The proportions of c-Met gene amplification in smokers and nonsmokers were 2.94％ and 1.35％， respectively. The c-Met gene amplification was detected in 1.23％ adenocarcinoma patients but none in squamous carcinoma patients. There was separately one patient harboring c-Met gene amplification in stage Ⅰ and stage Ⅲ（2.50％； 5.00％）.（2） The mutation rates of the EGFR and K-Ras gene were 42.59％ and 5.56％. The positive rate of EML4-ALK fusion gene was 12.04％. Conclusion The proportion of the gene amplification of cMet detected by FISH was consistent with c-Met expression levels analysed by qRT-PCR. The four driver genes were almost mutually exclusive. And no correlation was found between c-Met gene amplification and various clinicopathologic features such as age， sex， smoking status， histological types， and clinical stages.